Paper Details

  1. Home
  2. Paper Details

[Which is the best drug combination for the short-term therapy of tuberculosis? A prospective randomized study with 190 patients].

Author: BezelR, BrändliO, HäckiM, KarrerW, RubinS, RöthlisbergerK

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 190 patients with tuberculosis compared the effectiveness of two initial treatment regimens: pyrazinamide (Z) and ethambutol (E) in combination with isoniazid (H) and rifampicin (R). While both groups showed similar relapse rates (3.6%), the study found a trend towards faster conversion to negative cultures in the pyrazinamide group despite shorter initial treatment. All relapses occurred within the first year after treatment ended, and these patients had a longer delay before their cultures became negative compared to those who did not relapse. The study also found that family doctors tended to treat patients for a longer period (10 months) than recommended (9 months), possibly due to previous recommendations favoring longer treatment durations.
Paper Details　
Original Abstract of the Article :
190 patients with positive cultures for M. tuberculosis were treated in the initial phase as inpatients for 2-3 months at random with either pyrazinamide (Z) or ethambutol (E) in combination with isoniazid (H) and rifampicin (R). In the continuation phase as out-patients they were treated by their f...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/3906875

データ提供：米国国立医学図書館（NLM）

A Strategic Approach: Optimizing Tuberculosis Treatment

The world of [infectious disease] is constantly battling against [tuberculosis (TB)], a highly contagious disease that can be as devastating as a desert sandstorm. This study explores the effectiveness of different [drug combinations] for treating TB. The researchers aimed to determine the [optimal treatment regimen] for [short-term therapy of tuberculosis].

A Clear Path: Effective Treatment Regimens

The study found that [patients treated with pyrazinamide (Z)] showed a tendency for [more rapid conversion to negative cultures] despite a [shorter duration of initial-phase treatment]. It's like finding a clear path through the desert – the pyrazinamide-based regimen seemed to be more effective in clearing the infection, leading to a faster recovery. The study also observed a [low relapse rate] of [3.6%], which is encouraging for patients seeking a long-term cure.

Navigating the Desert of Tuberculosis: Adherence and Compliance

The study also highlights the importance of [adherence to treatment] for successful TB management. It's like a camel caravan staying on course – consistent adherence to the prescribed regimen is crucial for achieving a successful outcome. This study emphasizes the need for [close monitoring] and [patient education] to ensure adherence to treatment and prevent relapse.

Dr. Camel's Conclusion

The desert of tuberculosis can be a challenging landscape, but this study provides a valuable compass for navigating its complexities. It highlights the importance of finding the most effective drug combinations and ensuring consistent adherence to treatment. While further research is needed to optimize TB treatment strategies, this study offers a beacon of hope for patients seeking a cure for this debilitating disease.

Date :
  1. Date Completed 1986-01-03
  2. Date Revised 2016-11-23
Further Info :

Pubmed ID

3906875

DOI: Digital Object Identifier

3906875

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.